Acute exacerbation of pre-existing interstitial lung disease (ILD) associated with systemic anticancer therapy is recognized as a life-threatening adverse event of lung cancer treatment. Programmed cell death 1 (PD-1) checkpoint inhibitors, such as nivolumab, often induce pneumonitis in patients with cancer; however, the tolerance and safety of nivolumab for advanced lung cancer with ILD are unclear. We report a 72-year-old patient with lung cancer with pathologically proven idiopathic pulmonary fibrosis who was treated with nivolumab. She demonstrated pneumonitis with an organized pneumonia (OP) pattern, but no acute exacerbation of ILD featuring a diffuse alveolar damage (DAD) pattern. She was successfully treated with corticosteroid therapy, and maintained good disease control after the discontinuation of nivolumab. She also showed pseudoprogression of the primary tumor, implying infiltration of T-cells into the lung. These findings suggest that T-cell activation by nivolumab treatment might not be directly associated with acute ILD exacerbation, and that treatable OP might be a major pulmonary complication of nivolumab in patients with pre-existing ILD, similar to patients without underlying ILD. (J Nippon Med Sch 2019; 86: 43 47) 
Introduction
Interstitial lung disease (ILD) is considered a risk factor for lung carcinogenesis. In particular, the incidence of lung cancer in patients with idiopathic pulmonary fibrosis (IPF), the most common type of ILD, is significantly higher than that in the general population 1 . In patients with pre-existing ILD, cancer therapy including surgery, radiotherapy, and chemotherapy can cause acute exacerbation of ILD (AE-ILD), characterized by sudden, progressive, and severe respiratory failure with new lung opacities and pathological lesions of diffuse alveolar damage (DAD). AE-ILD is a fatal complication in many patients, contributing to the challenge of treating patients with lung cancer and ILD.
Nivolumab is a programmed death receptor 1 (PD-1)-specific monoclonal antibody used as a standard treatment for lung cancer 2, 3 . A recent meta-analysis showed that 4.2% of patients developed pneumonitis after nivolumab treatment for non-small-cell lung cancer (NSCLC) 4 . Organizing pneumonia (OP), ground glass opacity (GGO), and hypersensitivity pneumonitis are the main characteristics of pneumonitis induced by PD-1/PD ligand 1 (PD-L1) inhibitors 5, 6 . Nivolumab-induced ILD has shown a better response to corticosteroid therapy than pneumonitis induced by cytotoxic agents or epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) 7 . The incidence and pattern of pneumonitis induced by nivolumab in patients with ILD are not elusive, particularly in those with definitive IPF.
We herein report a patient with NSCLC with histologically proven IPF who was treated with nivolumab. She demonstrated pneumonitis with an OP pattern, but no DAD pattern, and was successfully treated with corticosteroid therapy. She maintained good disease control On day 57 of nivolumab treatment, chest CT revealed a reticular opacity and a slight increase in size of the primary tumor, consistent with an immune-related adverse event (irAE) associated with nivolumab (Fig. 3B) . The The patient noticed gradual dyspnea and a productive cough on day 99 of nivolumab treatment. Chest CT revealed new GGOs and consolidations in both lung fields (Fig. 3C, D) , and blood tests revealed serum levels of KL-6 (552.5 U/mL) that were higher than those measured be- 
Discussion
Herein we report a case of nivolumab-induced pneumonitis, which was confirmed by its recurrence after restarting nivolumab. HRCT showed consolidation with GGOs and a rapid response to corticosteroids that was consistent with an OP pattern. Importantly, an AE of underlying ILD was not involved in the present case. In general, since AE occurs more frequently in IPF than with other types of idiopathic interstitial pneumonitis (IIPs) 8 , definitively diagnosed IPF patients should be con- 
